CRBP
Income statement / Annual
Last year (2024), Corbus Pharmaceuticals Holdings, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Corbus Pharmaceuticals Holdings, Inc.'s net income was -$40.21 M.
See Corbus Pharmaceuticals Holdings, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$881.71 K |
$3.94 M |
$36.14 M |
$4.82 M |
$2.44 M |
$1.91 M |
$648.38 K |
| Cost of Revenue |
$600.00 K
|
$0.00
|
$1.49 M
|
$1.64 M
|
$0.00
|
$89.60 M
|
$48.61 M
|
$26.04 M
|
$15.44 M
|
$5.89 M
|
| Gross Profit |
-$600.00 K
|
$0.00
|
-$1.49 M
|
-$757.53 K
|
$3.94 M
|
-$53.46 M
|
-$43.79 M
|
-$23.60 M
|
-$13.53 M
|
-$5.24 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
-0.86
|
1
|
-1.48
|
-9.08
|
-9.67
|
-7.08
|
-8.08
|
| Research and Development Expenses |
$32.22 M
|
$31.17 M
|
$16.14 M
|
$36.45 M
|
$98.27 M
|
$89.60 M
|
$48.61 M
|
$26.04 M
|
$15.44 M
|
$5.89 M
|
| General & Administrative Expenses |
$16.50 M
|
$13.91 M
|
$18.70 M
|
$20.43 M
|
$28.48 M
|
$23.64 M
|
$12.96 M
|
$8.96 M
|
$6.46 M
|
$3.61 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$16.50 M
|
$13.91 M
|
$18.70 M
|
$20.43 M
|
$28.48 M
|
$23.64 M
|
$12.96 M
|
$8.96 M
|
$6.46 M
|
$3.61 M
|
| Other Expenses |
-$600.00 K
|
$0.00
|
-$1.49 M
|
-$1.64 M
|
$0.00
|
-$89.60 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$48.12 M
|
$45.08 M
|
$33.35 M
|
$55.23 M
|
$126.75 M
|
$23.64 M
|
$61.57 M
|
$35.00 M
|
$21.90 M
|
$9.50 M
|
| Cost And Expenses |
$48.72 M
|
$45.08 M
|
$34.84 M
|
$56.87 M
|
$126.75 M
|
$113.25 M
|
$61.57 M
|
$35.00 M
|
$21.90 M
|
$9.50 M
|
| Interest Income |
$6.31 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.23 M
|
$982.78 K
|
$183.11 K
|
$477.00
|
$3.42 K
|
| Interest Expense |
$1.87 M
|
$2.92 M
|
$2.13 M
|
$1.83 M
|
$1.03 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.44 K
|
| Depreciation & Amortization |
$600.00 K
|
$641.00 K
|
$1.49 M
|
$1.64 M
|
$1.69 M
|
$739.38 K
|
$493.94 K
|
$255.65 K
|
$87.66 K
|
$43.94 K
|
| EBITDA |
-$37.74 M |
-$40.11 M |
-$38.73 M |
-$54.35 M |
-$121.12 M |
-$76.37 M |
-$56.25 M |
-$32.31 M |
-$19.90 M |
-$8.81 M |
| EBITDA Ratio |
0
|
0
|
0
|
-61.64
|
-30.76
|
-2.11
|
-11.67
|
-13.24
|
-10.41
|
-13.59
|
| Operating Income Ratio |
0
|
0
|
0
|
-63.5
|
-31.19
|
-2.13
|
-11.77
|
-13.34
|
-10.46
|
-13.66
|
| Total Other Income/Expenses Net |
$8.51 M
|
$474.00 K
|
-$7.51 M
|
$10.35 M
|
$11.54 M
|
$5.65 M
|
$1.08 M
|
$141.20 K
|
-$13.62 K
|
$2.95 K
|
| Income Before Tax |
-$40.21 M
|
-$44.60 M
|
-$42.35 M
|
-$45.64 M
|
-$111.27 M
|
-$71.45 M
|
-$55.67 M
|
-$32.42 M
|
-$20.00 M
|
-$8.85 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-51.76
|
-28.26
|
-1.98
|
-11.54
|
-13.29
|
-10.46
|
-13.65
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$13.62 K
|
$2.44 K
|
| Net Income |
-$40.21 M
|
-$44.60 M
|
-$55.83 M
|
-$45.55 M
|
-$111.27 M
|
-$71.45 M
|
-$55.67 M
|
-$32.42 M
|
-$20.00 M
|
-$8.85 M
|
| Net Income Ratio |
0
|
0
|
0
|
-51.66
|
-28.26
|
-1.98
|
-11.54
|
-13.29
|
-10.46
|
-13.65
|
| EPS |
-3.68 |
-10.31 |
-10.15 |
-11.11 |
-42.74 |
-32.47 |
-29.3 |
-19.38 |
-14.58 |
-8.47 |
| EPS Diluted |
-3.68 |
-10.31 |
-10.15 |
-11.11 |
-42.74 |
-32.47 |
-29.3 |
-19.38 |
-14.58 |
-8.47 |
| Weighted Average Shares Out |
$10.92 M
|
$4.33 M
|
$4.17 M
|
$4.10 M
|
$2.60 M
|
$2.13 M
|
$1.90 M
|
$1.67 M
|
$1.37 M
|
$1.05 M
|
| Weighted Average Shares Out Diluted |
$10.92 M
|
$4.33 M
|
$4.17 M
|
$4.10 M
|
$2.60 M
|
$2.13 M
|
$1.90 M
|
$1.67 M
|
$1.37 M
|
$1.05 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
